Direxion Daily Healthcare Bull 3X ETF (CURE)
NYSEARCA: CURE · Real-Time Price · USD
130.60
+0.50 (0.38%)
Aug 12, 2026, 1:50 PM EDT - Market open
0.38% (1D)
| Assets | $169.96M |
| Expense Ratio | 0.94% |
| PE Ratio | 24.70 |
| Shares Out | 1.45M |
| Dividend (ttm) | $1.26 |
| Dividend Yield | 0.96% |
| Ex-Dividend Date | Jun 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 23.90% |
| Volume | 20,209 |
| Open | 127.30 |
| Previous Close | 130.10 |
| Day's Range | 125.40 - 131.41 |
| 52-Week Low | 69.33 |
| 52-Week High | 134.00 |
| Beta | 1.65 |
| Holdings | 72 |
| Inception Date | Jun 15, 2011 |
About CURE
Fund Home PageThe Direxion Daily Healthcare Bull 3X ETF (CURE) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund provides 3x levered exposure to a market cap weighted sub-index of the S&P 500 that tracks the performance of US listed health care companies. CURE was launched on Jun 15, 2011 and is issued by Direxion.
Asset Class Equity
Category Trading--Leveraged Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol CURE
ETF Provider Direxion
Index Tracked S&P Health Care Select Sector
Top 10 Holdings
73.87% of assets| Name | Symbol | Weight |
|---|---|---|
| Dreyfus Govt Cash Man Ins | n/a | 17.56% |
| Eli Lilly and Company | LLY | 10.02% |
| Health Care Select Sector Index Swap | n/a | 8.34% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 8.13% |
| Johnson & Johnson | JNJ | 6.96% |
| Goldman Finl Sq Trsry Inst 506 | n/a | 6.77% |
| AbbVie Inc. | ABBV | 4.89% |
| UnitedHealth Group Incorporated | UNH | 4.20% |
| Merck & Co., Inc. | MRK | 3.59% |
| Health Care Select Sector Index Swap | n/a | 3.40% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 23, 2026 | $0.3746 | Jun 30, 2026 |
| Mar 24, 2026 | $0.28317 | Mar 31, 2026 |
| Dec 23, 2025 | $0.29121 | Dec 31, 2025 |
| Sep 23, 2025 | $0.31013 | Sep 30, 2025 |
| Jun 24, 2025 | $0.30549 | Jul 1, 2025 |
| Mar 25, 2025 | $0.34549 | Apr 1, 2025 |
Performance
CURE had a total return of 91.56% in the past year, including dividends. Since the fund's inception, the average annual return has been 25.03%.
News
Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Glorious Success Limited in Reverse Takeover Transaction
VANCOUVER, British Columbia - TheNewswire - June 22 , 2026 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into a binding letter agreement dated June 22...
7 weeks ago - TheNewswire